Success rates for the development of new drugs is very low across all therapeutic areas and is lowest for oncology with only five per cent of compounds going into Phase I making it to market1. It is therefore important for Phase I and II trials to be better at distinguishing those agents that are going to succeed and those that are not. Costs of new drugs are growing and it is important to be able to focus resources on those that are most likely to make it all the way.

Clinical Trials Roundtable...

Knowing where and how to structure an outsourcing operation is a huge undertaking for any pharma company, no matter what size. Identifying the most common mistakes and forging a relationship that works for both parties and brings results is key.